Danaher Corporation (DHR) Financial Statements

Danaher Corporation

DHR · NYSE

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$24.57B	$23.88B	$23.89B	$26.64B	$24.80B	$22.28B	$17.91B	$17.05B
Cost of Revenue	$10.04B	$9.67B	$9.86B	$10.46B	$9.56B	$9.81B	$7.93B	$7.54B
Gross Profit	$14.52B	$14.21B	$14.03B	$16.19B	$15.24B	$12.47B	$9.98B	$9.51B
Research & Development	$1.60B	$1.58B	$1.50B	$1.53B	$1.50B	$1.35B	$1.13B	$1.06B
Selling, General & Administrative	$8.23B	$7.76B	$7.33B	$7.12B	$6.82B	$6.90B	$5.59B	$5.39B
Operating Income	$4.69B	$4.86B	$5.20B	$7.54B	$6.38B	$4.23B	$3.27B	$3.06B
Interest Expense	—	—	$286.00M	$204.00M	$231.00M	$275.00M	$108.00M	$137.00M
Other Income / (Expense)	-$222.00M	-$56.00M	-$175.00M	-$227.00M	$450.00M	$494.00M	$12.00M	$35.00M
Income Before Taxes	$4.23B	$4.65B	$5.04B	$7.15B	$6.51B	$4.50B	$3.31B	$2.96B
Provision for Income Taxes	$633.00M	$747.00M	$823.00M	$818.00M	$1.06B	$849.00M	$873.00M	$556.00M
Net Income	$3.61B	$3.90B	$4.76B	$7.21B	$6.43B	$3.65B	$3.01B	$2.65B
Basic EPS	$5.07	$5.33	$6.44	$9.80	$8.77	$4.97	$4.11	$3.78
Diluted EPS	$5.05	$5.29	$6.38	$9.66	$8.61	$4.89	$4.05	$3.74
Basic Shares Outstanding	712.70M	731.00M	736.50M	725.10M	714.60M	706.20M	715.00M	700.60M
Diluted Shares Outstanding	716.10M	737.20M	743.10M	737.10M	736.80M	718.70M	725.50M	710.20M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	$8.53	$8.47	$8.55	10	↑8 ↓1
Dec 2027	$9.26	$9.13	$9.36	10	↑8 ↓2
Dec 2028	$10.16	$9.90	$10.60	5	↑4 ↓0
Dec 2029	$12.40	$12.40	$12.40	1	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: DHR
Type: Stock
Sector: Industrials
Industry: Industrial Machinery/Components
Country: North America
Exchange: NYSE

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges-helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

Key Issues

Bullish view

The company operates across life sciences, diagnostics, and bioprocessing, giving it exposure to pharmaceutical and biotechnology demand. Analysts still collectively rate the shares Buy, suggesting they see a path for growth to improve.

Bearish view

Recent analyst commentary cited more conservative assumptions for growth, profitability, and future P/E multiples. Fiscal 2025 net income also declined to $3.6 billion from $3.9 billion despite higher revenue.

Analyst Consensus

See all

Buy

21 analysts

$199

Current

—

Low

$220

Average

—

High

Average target implies +10.56% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Deere & CompanyDE · NYSE$612.92